Amadid H, Rønn PF, Dunbar MBN, et al. - Researchers sought to evaluate lipid-lowering drug (LLD) use patterns during 1996-2017 and analyze lipid levels in relation to the use of LLDs and prevalent atherosclerotic cardiovascular disease (ASCVD). Four hundred four thousand three hundred eighty-nine people with type 2 diabetes living in Denmark during 1996-2017 were identified using a nationwide diabetes register. Individuals were tracked from January 1, 1996, or the date of type 2 diabetes diagnosis, until emigration, death, or January 1, 2017. LLD use has declined since 2012, with only 55% of those with type 2 diabetes using LLD in 2017. During the period 2010-2017, total cholesterol and LDL-C levels fell while triglycerides rose. In the Danish type 2 diabetes population, LLD use and LDL-C levels are far from optimal, and improving LLD use could reduce ASCVD events.